1. Sign our petition calling on Cochrane to withdraw their review of Exercise Therapy for CFS here.
    Dismiss Notice
  2. Guest, the 'News in Brief' for the week beginning 19th February 2024 is here.
    Dismiss Notice
  3. Welcome! To read the Core Purpose and Values of our forum, click here.
    Dismiss Notice

Interferon-γ and CXCL10 responses related to complaints in patients with Q fever fatigue syndrome

Discussion in 'ME/CFS research' started by Dolphin, Jun 5, 2018.

  1. Dolphin

    Dolphin Senior Member (Voting Rights)

    Messages:
    4,853
    https://link.springer.com/article/10.1007/s10096-018-3265-z

    Eur J Clin Microbiol Infect Dis. 2018 May 26. doi: 10.1007/s10096-018-3265-z. [Epub ahead of print]
    Interferon-γ and CXCL10 responses related to complaints in patients with Q fever fatigue syndrome.
    Raijmakers RPH1,2, Jansen AFM3,4, Keijmel SP3,4, Schoffelen T3,4, Scholzen A5, van der Meer JWM4, Joosten LAB4,6, Netea MG3,4,6, van Deuren M3,4,6, Bleeker-Rovers CP3,4,6.

    Abstract

    Approximately 20% of patients with acute Q fever develop Q fever fatigue syndrome (QFS), a debilitating fatigue syndrome.

    This study further investigates the role of C. burnetii-specific IFNγ, but also IL-2, CXCL9, CXCL10, and CXLC11 production in QFS patients. C. burnetii-specific IFNy, IL-2, CXCL9, CXCL10, and CXCL11 production were tested in ex vivo stimulated whole blood of QFS patients who recovered from their complaints (n = 8), QFS patients with persisting complaints (n = 27), and asymptomatic Q fever seropositive controls (n = 10).

    With the exclusion of one outlier, stimulation with C. burnetii revealed significantly higher IFNy and CXCL10 production in QFS patients with persisting complaints (medians 288.0 and 176.0 pg/mL, respectively) than in QFS patients who recovered from their complaints (medians 93.0 and 85.5 pg/mL, respectively) (p = 0.041 and 0.045, respectively).

    No significant differences between groups were found for C. burnetii-specific IL-2, CXCL9, and CXCL11 production.

    These findings point towards a difference in cell-mediated immunity in QFS patients with persisting complaints compared to those who recovered from their complaints.

    Such a difference may aid to eventually diagnose QFS more objectively and might serve as an indicator of its underlying etiology.

    KEYWORDS:
    CXCL10; Cell-mediated immunity; Coxiella burnetii; Interferon-gamma; Q fever; Q fever fatigue syndrome

    PMID:
    29804281
    DOI:
    10.1007/s10096-018-3265-z
     
  2. Esther12

    Esther12 Senior Member (Voting Rights)

    Messages:
    4,393
    Small study, and the exclusion of an outlier was required for them to report a significant difference... I guess we'll see if other groups replicate this or not.
     
    RedFox, Trish, Hutan and 2 others like this.
  3. Hutan

    Hutan Moderator Staff Member

    Messages:
    26,105
    Location:
    Aotearoa New Zealand
    Interesting to see this 2018 study where Raijmakers seemed to be suggesting that that there was immunological reason for QFS. A couple of years later he was trying to suggest that CBT is useful for fixing QFS. The fact that the small subjectively reported improvement didn't last didn't prompt doubt, only a suggestion that more research be done on CBT to make it more effective.
     
    RedFox, obeat, CRG and 1 other person like this.

Share This Page